Ipca Laboratories Limited (IPCALAB.BO)
INR 1363.95
(4.85%)
INR 1363.95
(4.85%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.91 Billion INR | -28.09% |
| 2022 | 30.94 Billion INR | 19.12% |
| 2021 | 25.97 Billion INR | 15.65% |
| 2020 | 22.46 Billion INR | 6.7% |
| 2019 | 21.05 Billion INR | 12.77% |
| 2018 | 18.66 Billion INR | 6.87% |
| 2017 | 17.46 Billion INR | 5.1% |
| 2016 | 16.62 Billion INR | 5.08% |
| 2015 | 15.81 Billion INR | 2.95% |
| 2014 | 15.36 Billion INR | 14.15% |
| 2013 | 13.46 Billion INR | 23.14% |
| 2012 | 10.93 Billion INR | 18.36% |
| 2011 | 9.23 Billion INR | 15.43% |
| 2010 | 8 Billion INR | 30.78% |
| 2009 | 6.11 Billion INR | -2.32% |
| 2008 | 6.26 Billion INR | 59.88% |
| 2007 | 3.91 Billion INR | 11.87% |
| 2006 | 3.5 Billion INR | 8.85% |
| 2005 | 3.21 Billion INR | 209.11% |
| 2004 | 1.04 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.68 Billion INR | -16.98% |
| 2023 Q2 | 11.25 Billion INR | 34.96% |
| 2023 Q1 | 8.33 Billion INR | 32.17% |
| 2023 FY | 22.25 Billion INR | -28.09% |
| 2023 Q3 | 11.24 Billion INR | -0.12% |
| 2023 Q4 | 6.84 Billion INR | -39.08% |
| 2022 Q1 | 7.99 Billion INR | 41.7% |
| 2022 Q3 | 8.34 Billion INR | 0.68% |
| 2022 Q4 | 6.3 Billion INR | -24.43% |
| 2022 Q2 | 8.29 Billion INR | 3.73% |
| 2022 FY | 30.94 Billion INR | 19.12% |
| 2021 FY | 25.97 Billion INR | 15.65% |
| 2021 Q2 | 6.91 Billion INR | 4.85% |
| 2021 Q3 | 6.82 Billion INR | -1.25% |
| 2021 Q4 | 5.64 Billion INR | -17.36% |
| 2021 Q1 | 6.59 Billion INR | 42.78% |
| 2020 FY | 22.46 Billion INR | 6.7% |
| 2020 Q4 | 4.61 Billion INR | -20.52% |
| 2020 Q3 | 5.81 Billion INR | -4.8% |
| 2020 Q2 | 6.1 Billion INR | 7.94% |
| 2020 Q1 | 5.65 Billion INR | 40.85% |
| 2019 FY | 21.05 Billion INR | 12.77% |
| 2019 Q3 | 5.66 Billion INR | -8.37% |
| 2019 Q4 | 4.01 Billion INR | -29.1% |
| 2019 Q1 | 5.19 Billion INR | 75.61% |
| 2019 Q2 | 6.17 Billion INR | 18.93% |
| 2018 Q2 | 5.7 Billion INR | 9.27% |
| 2018 FY | 18.66 Billion INR | 6.87% |
| 2018 Q4 | 2.95 Billion INR | -38.18% |
| 2018 Q3 | 4.78 Billion INR | -16.1% |
| 2018 Q1 | 5.21 Billion INR | 0.0% |
| 2017 FY | 17.46 Billion INR | 5.1% |
| 2016 FY | 16.62 Billion INR | 5.08% |
| 2015 FY | 15.81 Billion INR | 2.95% |
| 2014 FY | 15.36 Billion INR | 14.15% |
| 2013 FY | 13.46 Billion INR | 23.14% |
| 2012 FY | 10.93 Billion INR | 18.36% |
| 2011 FY | 9.23 Billion INR | 15.43% |
| 2010 FY | 8 Billion INR | 30.78% |
| 2009 FY | 6.11 Billion INR | -2.32% |
| 2008 FY | 6.26 Billion INR | 59.88% |
| 2007 FY | 3.91 Billion INR | 11.87% |
| 2006 FY | 3.5 Billion INR | 8.85% |
| 2005 FY | 3.21 Billion INR | 209.11% |
| 2004 FY | 1.04 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 12.318% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 64.535% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | -19.537% |
| Granules India Limited | 7.18 Billion INR | -93.737% |
| Indoco Remedies Limited | 4.74 Billion INR | -193.021% |
| Achyut Healthcare Limited | 1.6 Million INR | -864716.656% |
| Ajanta Pharma Limited | 30.46 Billion INR | 54.322% |
| Alkem Laboratories Limited | 32.83 Billion INR | 57.622% |
| Alpa Laboratories Limited | 156.14 Million INR | -8811.41% |
| Brooks Laboratories Limited | 51.18 Million INR | -27088.159% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -435.106% |
| Bajaj HealthCare Limited | 985.34 Million INR | -1312.186% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -880.46% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 85.487% |
| Eris Lifesciences Limited | 4.94 Billion INR | -181.511% |
| FDC Limited | 5.34 Billion INR | -160.163% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 79.405% |
| Gufic Biosciences Limited | 1.07 Billion INR | -1191.153% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -555.07% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -1699.162% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -30047.543% |
| Lasa Supergenerics Limited | 291.17 Million INR | -4678.895% |
| Laurus Labs Limited | 3.01 Billion INR | -362.166% |
| Lupin Limited | 95.67 Billion INR | 85.456% |
| Mankind Pharma Limited | 23.15 Billion INR | 39.9% |
| Medicamen Biotech Limited | 335.16 Million INR | -4051.632% |
| Medico Remedies Limited | 161.84 Million INR | -8497.724% |
| Megasoft Limited | 49.52 Million INR | -27995.018% |
| NATCO Pharma Limited | 10.05 Billion INR | -38.347% |
| Piramal Pharma Limited | 19.91 Billion INR | 30.125% |
| RPG Life Sciences Limited | 1.63 Billion INR | -750.804% |
| Sigachi Industries Limited | 579.88 Million INR | -2299.588% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 90.975% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -891.945% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -1376.54% |
| Unichem Laboratories Limited | 6.72 Billion INR | -106.886% |
| Wanbury Limited | 1.16 Billion INR | -1098.602% |
| Windlas Biotech Limited | 1 Billion INR | -1282.49% |
| ZIM Laboratories Limited | 1.01 Billion INR | -1273.554% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 67.77% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -352.252% |
| Divi's Laboratories Limited | 14.17 Billion INR | 1.8% |
| Hester Biosciences Limited | 908.84 Million INR | -1431.062% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -364.542% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -1166.156% |
| Bal Pharma Limited | 389.89 Million INR | -3468.93% |
| Strides Pharma Science Limited | 9.16 Billion INR | -51.871% |
| Venus Remedies Limited | 1.91 Billion INR | -626.14% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -352.605% |
| Nectar Lifesciences Limited | 625.55 Million INR | -2124.427% |
| Shilpa Medicare Limited | 2.18 Billion INR | -538.126% |
| Aarti Drugs Limited | 1.16 Billion INR | -1091.876% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -1166.372% |
| Suven Life Sciences Limited | 109.75 Million INR | -12578.724% |
| Ind-Swift Limited | 946.56 Million INR | -1370.039% |
| Valiant Laboratories Limited | 36.28 Million INR | -38244.677% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | -65.317% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -203.839% |
| Themis Medicare Limited | 782.85 Million INR | -1677.456% |
| Hikal Limited | 2.48 Billion INR | -459.654% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 35.044% |
| Sequent Scientific Limited | 2.9 Billion INR | -379.525% |
| Novartis India Limited | 470.1 Million INR | -2859.987% |
| Wockhardt Limited | 6.4 Billion INR | -117.42% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 3.73% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -85743.05% |
| Neuland Laboratories Limited | 2.92 Billion INR | -374.952% |
| Morepen Laboratories Limited | 1.98 Billion INR | -600.138% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -3273.906% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -1957.97% |